

BIOGEN IDEC INC  
Form 8-K  
July 28, 2004

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): July 28, 2004

**Biogen Idec Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**

**0-19311**

**33-0112644**

(State or other jurisdiction of  
incorporation)

(Commission File Number)

(IRS Employer Identification  
No.)

**14 Cambridge Center, Cambridge, Massachusetts 02142**

(Address of principal executive offices) (zip code)

Registrant's telephone number, including area code: **(617) 679-2000**

**Not Applicable**

(Former name or former address, if changed since last report)

---

**TABLE OF CONTENTS**

Item 12. Disclosure of Results of Operations and Financial Condition

SIGNATURES

EXHIBIT INDEX

EX-99.1 PRESS RELEASE

---

**Table of Contents**

**Item 12. Disclosure of Results of Operations and Financial Condition.**

The press release attached as Exhibit 99.1 includes information with respect to the following: (a) the Registrant's adjusted non-GAAP earnings per share and net income for the second quarter and the first six months of 2004, and (b) the Registrant's adjusted pro forma non-GAAP earnings per share, net income and revenues for the second quarter and the first six months of 2003. These are non-GAAP financial measures.

The non-GAAP financial measures for the second quarter and the first six months of 2004 exclude non-operational and unusual activities and transactions. The non-GAAP financial measures for the second quarter and the first six months of 2003 include revenue and expenses from the former Biogen, Inc. and exclude non-operational and unusual activities and transactions of former Biogen, Inc. and IDEC Pharmaceuticals Corporation.

Management believes that the non-GAAP financial measures provide useful information to investors. In particular, management believes that they allow investors to monitor and evaluate the Registrant's ongoing operating results and trends and gain a better understanding of the Registrant's business, period-to-period performance, and prospects for future performance.

This press release is being furnished pursuant to Item 12 of this Current Report on Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that Section, nor shall such documents be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Biogen Idec Inc.  
(Registrant)

Date: July 28, 2004

/s/ Thomas J. Bucknum

\_\_\_\_\_  
Thomas J. Bucknum  
Executive Vice President, General Counsel

**Table of Contents**

EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Description</b>
99.1	The Registrant's Press Release dated July 28, 2004.